GSK Pushing For ADOPTion Of Avandia For First-Line Type 2 Diabetes Therapy
Executive Summary
GlaxoSmithKline plans to use the results of its ADOPT study to establish its thiazolidinedioneAvandia as the standard first-line treatment for type 2 diabetes